Oldenburg Capital Partners S.à.r.l., a société à responsabilité limitée incorporated under the laws of the Grand Duchy of Luxembourg, is registered with the Luxembourg Trade and Companies Register (RCS) under number B290365, with its registered office at 18, rue Robert Stumper L-2557 Luxembourg.



The company is registered with the Commission de Surveillance du Secteur Financier (CSSF) as an alternative investment fund manager within the meaning of Article 3(3) of the Luxembourg Law of 12 July 2013 on alternative investment fund managers, as amended (the "AIFM Law"), and acts in this capacity for a Luxembourg special limited partnership (SCSp) formed under its management.



The information contained on this website is provided for general information purposes only and is intended exclusively for professional investors as defined under Directive 2011/61/EU and the AIFM Law.



This website does not constitute an offer or solicitation to subscribe for, purchase, or sell any interests or securities, nor does it constitute a public offer or marketing of any alternative investment fund managed by Oldenburg Capital Partners S.à.r.l. within the meaning of the AIFM Law or any other applicable legislation. No information on this website should be construed as investment advice or a recommendation.



If you are not a professional investor or are otherwise restricted under applicable law from accessing fund-related information, you are kindly requested to refrain from further navigation.

Healthcare

Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms

Published 19 May, 2026


The FDA's leadership change has sent a short-term lift through biotech markets. But a short-term rally and a settled outlook are very different things.

With two of the agency's top drug oversight positions now held by acting heads, the question for investors is less about Makary and more about what comes next. The biotech market is increasingly trading not just on clinical data, but on Washington dynamics, and a prolonged leadership vacuum is likely to mean more delays and less regulatory predictability for the sector.

Our Founding Partner, Patrice Mesnier shared his analysis with Reuters on what the shift means for capital markets, the realistic candidates to lead the agency, and why the White House faces a credibility choice as much as a personnel one.

Full piece here: 
https://www.reuters.com/legal/transactional/makary-exit-may-temporarily-lift-biotech-sentiment-fda-leadership-vacuum-looms-2026-05-13/
 
Quotes from Oldenburg

“The market will react less to the individual name than to what the appointment signals about the future direction of the FDA.”

“If the next commissioner is perceived as ideological rather than technocratic, biotech volatility could extend materially.”

— Patrice Mesnier, Founding Partner